4. Williams ED, MoralesAM,Horn RC. Thyroid car–
cinoma and Cushing's syndrome. A report of two
cases with a review of the common features of the
'non-endocrine' tumours associatedwithCushing's
syndrome. J Clin Patholl968;21:129-35.
5. BergholmU.Medullary thyroid carcinoma in Swe–
den. Thesis. Acta Universitatis Upsaliensis
1989;189:1-32.
6. Rosai J, CarcangiuML, DeLellis RA. Atlas of tu–
mor pathology. Third series, fascicle 5: Tumors of
the thyroid gland. Washington DC: Arrned Forces
Institute ofPathology, 1992.
7. WickMJ.Clinical andmolecular aspects ofmultip–
le endocrine neoplasia. Clin LabMed 1997;17:39-
57.
8. Ah!manH,WängbergB,NilssonO, JohanssonBG,
Jacobsson
A,
LindstedtG. KromograninA:en "ny"
tumörmarkör. KliniskKemi iNorden 1996;8(2):45-
52.
9. Breimer LH, Maelutyre I, Zaidi M. Peptides from
the calcitonin genes: molecular genetics, structure
and function. Biochem J 1988;255:377-90.
10.
Macintyre
I.
Calcitonin: physiology, biosynthesis,
secretion, metabolism, and mode of action. I De–
Groot
LJ,
BesserM, BurgerHG, Jarneson JL, Lori–
aux DL, Marshall JC, Ode!! WD, Potts JT Jr, Ru–
bensteinAH, eds. Endocrinology 3rded., vol2. Phi–
ladelphia: WB Saunders 1995:978-89.
11. Becker
KL,
NylenES, Cohen R, Snider
RH.
Calci–
tonin: structure, molecular biology, and actions. I
Bilezikian JP, RaiszLG, RodanGA, red. Principles
of bone biology. San Diego: Academic Press,
1996:471-89.
12. Wimalawansa SJ. Calcitonin gene-related peptide
and its receptors: molecular genetics, physiology,
pathophysiology, and therapentic potentials. Endo–
crRev 1996;17:533-85.
13.
Dandona P, Nix D,Wilson MF, Aljada A, Love J,
Assicot M, Bohuon C. Procalcitonin increase after
endatoxin injection in normal subjects. J Clin En–
docrinol Metab 1994;79:1605-8.
14. T!llrringO. Calcitonin response to calcium clamp in
man. Standardized calcium infusion in healthy sub–
jects and patients with osteopenia-associated di–
seases. Thesis. Stockholm: Karolinska institutet
1985:1-61.
15. Gautvik
KM.
Medullary carcinoma of the thyroid.
An update of diagnostic and prognostic factors.
Scand J Clin Lab Invest Suppll991;206:85-92.
16. ErdoganMF, Giillii S, Baskal N, UysalAR, Kamel
N, Erdogan G. Omeprazole: calcitonin stimulation
test for the diagnosis, foliow-up and family screen–
ing in medullary thyroid carcinoma. J Clin Endo–
crinol Metab 1997;82:897-9.
17. CarterWB, Heath H III. Clinically useful calcito–
nin assays. Trends Endocrinol Metab 1990;1:288-
42
91.
18. Guyetant S, RonsseletM-C, DurigonM, Chappard
D, FrancB,GuerinO, Saint-Andre J-P. Sex-related
C-cell hyperplasia in the normal human thyroid: a
quantitative autopsy study. J Clin Endocrinol Me–
tab 1997;82:42-7.
19. LiVolsiVA. Editorial: C cell hyperplasia/neoplasia.
J Clin EndocrinolMetab 1997;82:39-41.
20. Scopsi L,DiPalmaS, Ferrari C, Holst JJ, Rehfeld J,
Rilke F. C-cell hyperplasia accompanying thyroid
diseases other thanmedullary carcinoma: an immu–
nocytochemical studybymeans ofantibodies to cal–
citonin and somatostatin. Mod Pathol 1991 ;4:297-
304.
21. Horvit PM, Gage! RF. Editorial: The goitrous pa–
tientwith an elevated serum calcitonin- what todo?
J Clin Endocrinol Metab 1997;82:335-7.
22. Body JJ, Heath H
III.
"Nonspecific" increases in
plasma immunoreactive calcitonin in healthy indi–
viduals: discrimination frommedullary thyroid car–
dnorna by a new extraction technique. Clin Chem
1984;30:511-4.
23. The Immunoassay Kit Directory, seriesA (Peptide
Hormones). KluwerAcademic Publishers, Lancas–
ter, 1994;3(1):28-40.
24. The Immunoassay Kit Directory, seriesA (Proteins
andTumourMarkers). KluwerAcademicPublishers,
Lancaster, 1995;3(3):930-1.
25. Perdrisot R, Bigorgne JC, Guilloteau D, Jallet P.
Monoclonal immunoradiometric assayofcalcitonin
improves investigation of familial medullary thy–
roid carcinoma. ClinChem 1990;36:381-3.
26. Weissel M, Kainz H, Ty! E, Ogunyemi E,Wolosz–
cukW. Clinical evaluation of new assays for deter–
mination of serum calcitonin concentrations. Acta
Endocrinol (Copenh) 1991;124:540-4.
27. van Lathem JJM, Vermaak WJH, Kuyl JM, Mol–
lentzeW, Jansen S,Wolmarans L, Pelser H, Barry
R, Kruger AJ, Wolfaardt M, Nel CJC. Experience
with aprovocative test ofcalcitonin release as apro–
spective screening for preclinicalmedullary thyroid
carcinoma inMen type 2A family members. J Clin
LabAnalysis 1992;6:384-90.
28. Motte P, Vauzelle P, Gardet P,Ghillani P, CaillouB,
ParmentierC,BohounC,BelletD.Construction and
clinical validatian of a sensitive and specific assay
for serum rnature calcitonin usingmonoclonal anti–
peptide antibodies. Clin ChimActa 1988;174:35-
54.
29. Seth R, Motte P, Kehely A,Wimalawansa SJ, Self
CH, Bellet D, Bohuon C, Maelutyre
I.
A sensitive
and specific two-site enzyme-immunoassay for hu–
man calcitonin using monoclonal antibodies. J En–
docrinol1988;119:351-7.
30. ZinkA, Blind E, Raue
F.
Determination of serum
calcitonin by immunometric two-site assays in nor-
Klinisk Kemi
i
Norden
2,
1997
